has significant changes Balance by Quarter Change Q3–20 Q4–19 Q3–20 VS Q4–19 (MB) (MB) % Trade and other receivables 3,067.2 2,268.6 798.6 35.2 Contract assets - unbilled receivables 1,611.6 1,705.0
- 2020 Balance by Quarter Change Q2–20 Q1–20 Q2–19 Q2–20 VS Q1–20 Q2–20 VS Q2–19 (Million Baht: MB) (MB) % (MB) % Total Revenue 1,187.6 1,231.7 1,729.6 (44.1) (3.6) (542.0) (31.3) Total Operating Expenses
was equal to 26.3 MB which it was the payment of interest from late payment of a large trade receivable. - 2 - Topic Annual Balance Change 2020 2019 2020 VS 2019 (MB) (MB) % Sales and Services Income
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
sales experienced a major decline especially revenue generated via traditional trade channels. The Company is aware of the situation and its impacts and already overhauled its strategies and marketing
increased by Baht 34.50 million, mainly due to the following reasons: • Trade and other receivables increased by Baht 9 9 . 4 2 million, primarily due to the increase of trade receivables-third party of
570.6 million baht, decreased 25.3 million baht or 4.2 percent compared to current assets as of December 31, 2019. Mostly due to cash equivalents decreased 9.1 million baht. Trade and other receivables
contracts were higher than the exchange rates at the end of the quarter. Assets Items that has significant changes Balance by Quarter Change Q1–18 Q4–17 Q1–18 VS Q4–17 (MB) (MB) % Trade and Other Payables
change in the first half of this year as well as increasing number of beds in service. Operation : Consolidated Profit & Loss Statement 4Q 4Q % 12 mth 12 mth % Unit : THB million 2018 2017 change 2018 2017